Krystal Biotech, Inc.
KRYS
$197.93
-$2.04-1.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 192.00% | 146.22% | 3,734.01% | 423.23% | -66.34% |
| Total Depreciation and Amortization | -3.21% | -65.86% | -9.84% | -59.41% | -45.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -195.27% | 10.98% | 65.58% | 39.99% | 113.86% |
| Change in Net Operating Assets | -253.20% | 101.48% | -394.16% | 78.25% | 291.78% |
| Cash from Operations | -32.62% | 1,365.09% | 94.92% | 830.68% | 377.29% |
| Capital Expenditure | -62.91% | -68.35% | -392.38% | 56.63% | 41.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 92.24% | 52.69% | -98.22% | -898.16% | -577.30% |
| Cash from Investing | 87.51% | 45.62% | -110.81% | -724.59% | -132.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.37% | -83.12% | -90.84% | -7.29% | -74.87% |
| Repurchase of Common Stock | -- | -- | -158.60% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.22% | -83.12% | -217.79% | -7.29% | -74.87% |
| Foreign Exchange rate Adjustments | -207.34% | 414.24% | -8.56% | -324.29% | 2,283.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.60% | 440.84% | -5,423.75% | -95.14% | -71.06% |